Over 10 mio. titler Fri fragt ved køb over 499,- Hurtig levering Forlænget returret til 31/01/25

Treating Life-Threatening Bleedings

- Development of Recombinant Coagulation Factor VIIa

  • Format
  • Bog, paperback
  • Engelsk

Beskrivelse

Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.

Læs hele beskrivelsen
Detaljer
  • SprogEngelsk
  • Sidetal214
  • Udgivelsesdato06-07-2017
  • ISBN139780128124390
  • Forlag Academic Press Inc
  • FormatPaperback
Størrelse og vægt
  • Vægt360 g
  • coffee cup img
    10 cm
    book img
    15,2 cm
    22,9 cm

    Findes i disse kategorier...

    Se andre, der handler om...

    Te Hemophilia Mechanism of action Thrombocytopenia Heparin Dosing Hemophilia treatment Queen Victoria's Family Acquired hemophilia Activated prothrombin complex concentrates (aPCC) Approved in hemophilia patients with inhibitors in 1996 (EU) and 1999 (the United States) Approved for use in Glanzmann's patients in 2004 Approval of rFVIIa BHK cells Baby hamster kidney cell line Bypass treatment Clearance rate of rFVIIa Coagulation FVIIa Classical bleeding disease Cost evaluation Cell-based hemostasis model Different descriptions of drug development Dosing of rFVIIa in hemophilia Bypass treatment in hemophilia Development of rFVIIa FVII deficiency compassionate use study of rFVIIa FXI deficiency Hemophilia patients with inhibitors Hemophilia with inhibitors Logiparin Intracerebral bleedings Jan Waldenström Long-term rFVIIa treatment Orphan drug status Hemostatic drug Hemostasis mechanism Orthopedic surgery with rFVIIa Patent on therapeutic methods for treating blood clotting defects with FVIIa Recombinant FVIIa produced in mammalian cells Pharmacokinetics of rFVIIa RFVIIa and TE/DIC Prophylaxis in hemophilia Inga Marie Nilsson Recombinant FVIIa Recombinant technique for production of human proteins RFVIIa binding to platelets Hemophilia inheritance Successful use of rFVIIa The University Hospital of Malmö Trauma Patients Treatment of inhibitor patients Tsarevich Alexis of Russia Learnings from developing new drugs Modified heparins Plasma-derived FVIIa Prince Leopold of Great Britain RFVIIa Treatment of hemophilia Treatment of hemophilia patients with inhibitors Prophylactic effect of rFVIIa Tinzaparin Surgery in inhibitor patients
    Machine Name: SAXO084